٩	Methodology Checklist 4: Case-control studies			
SIG	1			
Study identification (Include author, title, year of publication, journal title, pages)				
Guideli	ne topic: Key Question No:	Reviewer:		
Before	completing this checklist, consider:			
1.	Is the paper really a case-control study? If in doubt, check the study design algorithm available make sure you have the correct checklist.	ilable from SGN and		
2.	Is the paper relevant to key question? Analyse using PICO (Patient or Population Interver Outcome). IF NO REJECT (give reason below). IF YES complete the checklist.	ition Comparison		
Reason	for rejection: Reason for rejection: 1. Paper not relevant to key question $\Box$ 2. Other rea	son 🗆 (please specify):		
SECT	ON 1: INTERNAL VALIDITY			
In an v	ell conducted case control study:	Does this study do it?		
1.1	The study addresses an appropriate and clearly focused question. <sup>1</sup>	Yes 🗆 No 🗆		
		Can't say □		
	TION OF SUBJECTS			
1.2	The cases and controls are taken from comparable populations.	Yes 🗆 No 🗆		
		Can't say □		
1.3	The same exclusion criteria are used for both cases and controls. <sup>III</sup>	Yes 🗆 No 🗆		
		Can't say □		
1.4	What percentage of each group (cases and controls) participated in the study? <sup>iv</sup>	Cases:		
		Controls:		
1.5	Comparison is made between participants and non-participants to establish their	Yes 🗆 No 🗆		
	similarities or differences. <sup>v</sup>	Can't say □		
1.6	Cases are clearly defined and differentiated from controls.vi	Yes 🗆 No 🗆		
		Can't say □		
1.7	It is clearly established that controls are non-cases.vii	Yes 🗆 No 🗆		
		Can't say □		

File name : Checklist 4 – Case Control Studies	Version 2.0	28/05/2012
Produced by: Carolyn Sleith	Page 1 of 3	Review date: None

ASSES	ASSESSMENT					
1.8	Measures will have been taken to prevent knowledge of primary exposure influencing case ascertainment. <sup>viii</sup>	Yes 🗆	No 🗆			
		Can't say □	Does not apply □			
1.9	Exposure status is measured in a standard, valid and reliable way. <sup>ix</sup>	Yes 🗆	No 🗆			
		Can't say □				
CONF	OUNDING					
1.10	The main potential confounders are identified and taken into account in the design and analysis. <sup>x</sup>	Yes 🗆	No 🗆			
		Can't say □				
STATI	STATISTICAL ANALYSIS					
1.11	Confidence intervals are provided. <sup>xi</sup>	Yes 🗆	No 🗆			
SECT	TION 2: OVERALL ASSESSMENT OF THE STUDY					
<b>SECT</b> 2.1	TION 2: OVERALL ASSESSMENT OF THE STUDY How well was the study done to minimise the risk of bias or confounding? <sup>xii</sup>	High qualit	/ (++) 🗆			
		High quality Acceptable				
			(+) 🗆			
		Acceptable Unaccepta	(+) 🗆			
2.1	How well was the study done to minimise the risk of bias or confounding? <sup>xii</sup> Taking into account clinical considerations, your evaluation of the	Acceptable Unaccepta reject 0 □	(+) □ ble – No □			
2.1	How well was the study done to minimise the risk of bias or confounding? <sup>xii</sup> Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, do you think there is	Acceptable Unaccepta reject 0 Yes	(+) □ ble – No □			
2.1	How well was the study done to minimise the risk of bias or confounding? <sup>xii</sup> Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, do you think there is clear evidence of an association between exposure and outcome? Are the results of this study directly applicable to the patient group targeted by this	Acceptable Unacceptal reject 0 Yes Can't say Yes Yes ent of the stud	(+)			
2.1 2.2 2.3	How well was the study done to minimise the risk of bias or confounding? <sup>xii</sup> Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, do you think there is clear evidence of an association between exposure and outcome? Are the results of this study directly applicable to the patient group targeted by this guideline? <b>Notes.</b> Summarise the authors conclusions. Add any comments on your own assessme	Acceptable Unacceptal reject 0 Yes Can't say Yes Yes ent of the stud	(+)			
2.1 2.2 2.3	How well was the study done to minimise the risk of bias or confounding? <sup>xii</sup> Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, do you think there is clear evidence of an association between exposure and outcome? Are the results of this study directly applicable to the patient group targeted by this guideline? <b>Notes.</b> Summarise the authors conclusions. Add any comments on your own assessme	Acceptable Unacceptal reject 0 Yes Can't say Yes Yes ent of the stud	(+)			

<sup>&</sup>lt;sup>ii</sup> Study participants may be selected from the target population (all individuals to which the results of the study could be applied), the source population (a defined subset of the target population from which participants are selected), or from a

File name : Checklist 4 – Case Control Studies	Version 2.0	28/05/2012
Produced by: Carolyn Sleith	Page 2 of 3	Review date: None

<sup>&</sup>lt;sup>i</sup> Unless a clear and well defined question is specified in the report of the review, it will be difficult to assess how well it has met its objectives or how relevant it is to the question you are trying to answer on the basis of the conclusions.

pool of eligible subjects (a clearly defined and counted group selected from the source population. If the study does not include clear definitions of the source population it should be rejected.

<sup>iii</sup> All selection and exclusion criteria should be applied equally to cases and controls. Failure to do so may introduce a significant degree of bias into the results of the study.

<sup>iv</sup> Differences between the eligible population and the participants are important, as they may influence the validity of the study. A participation rate can be calculated by dividing the number of study participants by the number of eligible subjects. It is more useful if calculated separately for cases and controls. If the participation rate is low, or there is a large difference between the two groups, the study results may well be invalid due to differences between participants and non-participants. In these circumstances, the study should be downgraded, and rejected if the differences are very large.

<sup>v</sup> Even if participation rates are comparable and acceptable, it is still possible that the participants selected to act as cases or controls may differ from other members of the source population in some significant way. A well conducted casecontrol study will look at samples of the non-participants among the source population to ensure that the participants are a truly representative sample.

<sup>vi</sup> The method of selection of cases is of critical importance to the validity of the study. Investigators have to be certain that cases are truly cases, but must balance this with the need to ensure that the cases admitted into the study are representative of the eligible population. The issues involved in case selection are complex, and should ideally be evaluated by someone with a good understanding of the design of case-control studies. If the study does not comment on how cases were selected, it is probably safest to reject it as a source of evidence.

<sup>vii</sup> Just as it is important to be sure that cases are true cases, it is important to be sure that controls do not have the outcome under investigation. Control subjects should be chosen so that information on exposure status can be obtained or assessed in a similar way to that used for the selection of cases. If the methods of control selection are not described, the study should be rejected. If different methods of selection are used for cases and controls the study should be evaluated by someone with a good understanding of the design of case-control studies.

<sup>viii</sup> If there is a possibility that case ascertainment can be influenced by knowledge of exposure status, assessment of any association is likely to be biased. A well conducted study should take this into account in the design of the study.

<sup>ix</sup> The primary outcome measures used should be clearly stated in the study. **If the outcome measures are not stated, or the study bases its main conclusions on secondary outcomes, the study should be rejected.** Where outcome measures require any degree of subjectivity, some evidence should be provided that the measures used are reliable and have been validated prior to their use in the study.

<sup>x</sup> Confounding is the distortion of a link between exposure and outcome by another factor that is associated with both exposure and outcome. The possible presence of confounding factors is one of the principal reasons why observational studies are not more highly rated as a source of evidence. The study should indicate which potential confounders have been considered, and how they have been allowed for in the analysis. Clinical judgement should be applied to consider whether all likely confounders have been considered. If the measures used to address confounding are considered inadequate, the study should be downgraded or rejected. A study that does not address the possibility of confounding should be rejected.

<sup>xi</sup> Confidence limits are the preferred method for indicating the precision of statistical results, and can be used to differentiate between an inconclusive study and a study that shows no effect. Studies that report a single value with no assessment of precision should be treated with extreme caution.

x<sup>ii</sup> Rate the overall methodological quality of the study, using the following as a guide: **High quality** (++): Majority of criteria met. Little or no risk of bias. Results unlikely to be changed by further research. **Acceptable** (+): Most criteria met. Some flaws in the study with an associated risk of bias, Conclusions may change in the light of further studies. **Low quality** (0): Either most criteria not met, or significant flaws relating to key aspects of study design. Conclusions likely to change in the light of further studies.

File name : Checklist 4 – Case Control Studies	Version 2.0	28/05/2012
Produced by: Carolyn Sleith	Page 3 of 3	Review date: None